These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 29684339)

  • 1. Sorafenib-induced tumor lysis syndrome in a patient with metastatic hepatocellular carcinoma.
    Imam SZ; Zahid MF; Maqbool MA
    Hematol Oncol Stem Cell Ther; 2020 Sep; 13(3):168-170. PubMed ID: 29684339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor lysis syndrome after sorafenib for hepatocellular carcinoma: a case report.
    Shiozawa K; Watanabe M; Takenaka H; Nagai H; Ishii K; Sakai K; Sumino Y
    Hepatogastroenterology; 2010; 57(101):688-90. PubMed ID: 21033210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spontaneous tumour lysis syndrome in hepatocellular carcinoma presenting with hypocalcemic tetany: An unusual case and systematic literature review.
    Agarwala R; Batta A; Suryadevera V; Kumar V; Sharma V; Rana SS
    Clin Res Hepatol Gastroenterol; 2017 Jun; 41(3):e29-e31. PubMed ID: 27743982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
    Joshita S; Yoshizawa K; Sano K; Kobayashi S; Sekiguchi T; Morita S; Kamijo A; Komatsu M; Umemura T; Ichijo T; Matsumoto A; Tanaka E
    Intern Med; 2010; 49(11):991-4. PubMed ID: 20519814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. All that glitters: sorafenib.
    Abbass K; Dewani S; Markert R; Kaplon MK; Baumann MA
    Intern Med; 2011; 50(7):797. PubMed ID: 21467725
    [No Abstract]   [Full Text] [Related]  

  • 6. Sintilimab plus sorafenib: a novel regimen for hepatocellular carcinoma.
    Liu X; Yi Y
    Immunotherapy; 2021 Dec; 13(17):1387-1393. PubMed ID: 34665016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective clinical trial on sorafenib treatment of hepatocellular carcinoma before liver transplantation.
    Eilard MS; Andersson M; Naredi P; Geronymakis C; Lindnér P; Cahlin C; Bennet W; Rizell M
    BMC Cancer; 2019 Jun; 19(1):568. PubMed ID: 31185950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facial nodulocystic eruption induced by sorafenib in a patient with hepatocellular carcinoma.
    Duran-Vian C; Gómez-Fernández C; Navarro-Fernández I; Del Cura LR; Alonso-Buznego L; González-Vela MC; González-López MA
    Indian J Dermatol Venereol Leprol; 2020; 86(4):409-411. PubMed ID: 32415051
    [No Abstract]   [Full Text] [Related]  

  • 10. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma.
    Goyal L; Zheng H; Abrams TA; Miksad R; Bullock AJ; Allen JN; Yurgelun MB; Clark JW; Kambadakone A; Muzikansky A; Knowles M; Galway A; Afflitto AJ; Dinicola CF; Regan E; Hato T; Mamessier E; Shigeta K; Jain RK; Duda DG; Zhu AX
    Clin Cancer Res; 2019 Jan; 25(1):80-89. PubMed ID: 30190369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Lysis Syndrome: A Serious Complication of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.
    Jiang RD; Jian WC; Jin N; Zhang ZL; Li T
    Am J Med; 2016 Sep; 129(9):e173-6. PubMed ID: 27155110
    [No Abstract]   [Full Text] [Related]  

  • 12. Rasburicase for huge hepatocellular carcinoma with tumor lysis syndrome: case report.
    Chao CT; Chiang CK
    Med Princ Pract; 2012; 21(5):498-500. PubMed ID: 22687814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
    Qin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla TM; Tomasello G; Boisserie F; Hou J; Li X; Song J; Zhu AX
    Future Oncol; 2019 Jun; 15(16):1811-1822. PubMed ID: 30969136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of cytotoxic chemotherapy in hepatocellular carcinoma after first-line treatment with sorafenib.
    da Fonseca LG; Marta GN; Braghiroli MIFM; Chagas AL; Carrilho FJ; Hoff PM; Sabbaga J
    BMC Cancer; 2018 Dec; 18(1):1250. PubMed ID: 30545331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, phase 3 trial.
    Kudo M; Ueshima K; Yokosuka O; Ogasawara S; Obi S; Izumi N; Aikata H; Nagano H; Hatano E; Sasaki Y; Hino K; Kumada T; Yamamoto K; Imai Y; Iwadou S; Ogawa C; Okusaka T; Kanai F; Akazawa K; Yoshimura KI; Johnson P; Arai Y;
    Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):424-432. PubMed ID: 29631810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lenvatinib-induced tumor lysis syndrome in a patient with advanced hepatocellular carcinoma: a case report.
    Shimizu Y; Sunagozaka H; Yamagata K; Hirai H; Miura M; Yonemoto Y; Naito Y; Hasatani K; Yoshikawa J; Aoyagi H; Kaneko S
    Clin J Gastroenterol; 2021 Apr; 14(2):645-649. PubMed ID: 33389590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
    Hayashi T; Yamashita T; Terashima T; Suda T; Okada H; Asahina Y; Hayashi T; Hara Y; Nio K; Sunagozaka H; Takatori H; Arai K; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S
    BMC Cancer; 2017 Dec; 17(1):870. PubMed ID: 29258450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leukocytoclastic vasculitis associated with sorafenib treatment for hepatocellular carcinoma.
    Prejac J; Kekez D; Belev B; Kocić L; Bulimbašić S; Pleština S
    Anticancer Drugs; 2020 Jan; 31(1):76-79. PubMed ID: 31567309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute tumor lysis syndrome after transcatheter chemoembolization of hepatocellular carcinoma.
    Burney IA
    South Med J; 1998 May; 91(5):467-70. PubMed ID: 9598857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.